Physician profile
Robert M Klein
NPI 1235196452
$4,281.12
in general payments reported to CMS, 2019-2025
28 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $139 · 2021: $153 · 2022: $75.00 · 2023: $314 · 2024: $1,115 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189 · Education: $230 · Consulting Fee: $34.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.90 |
| Education | $229.94 |
| Consulting Fee | $34.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $725.21 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $517.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $440.15 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $401.73 | 2019-2024 | |
| Alk-Abello, INC | $327.54 | 2020-2023 | Odactra |
| Regeneron Healthcare Solutions, INC. | $286.92 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $201.31 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $169.44 | 2021-2025 | |
| Csl Behring | $161.87 | 2019-2025 | Andembry |
| Adma Biomanufacturing LLC | $155.10 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $115.35 | 2024-2025 | |
| Lilly USA, LLC | $114.64 | 2024-2025 | Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $109.75 | 2024-2025 | Hyqvia, Eohilia, Takhzyro |
| Leo Pharma INC. | $93.39 | 2024-2025 | Anzupgo |
| Organon LLC | $76.52 | 2025 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $74.32 | 2020 | |
| Cycle Pharmaceuticals INC | $72.25 | 2025 | Sajazir |
| Azurity Pharmaceuticals, INC. | $33.25 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $32.45 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.33 | 2019 | |
| Greer Laboratories, INC. | $22.37 | 2024 | Oralair |
| Blueprint Medicines Corporation | $19.28 | 2025 | Ayvakit |
| Pharming Healthcare, INC. | $19.15 | 2025 | Ruconest |
| Grifols USA, LLC | $17.70 | 2023 | Xembify |
| Amgen INC. | $17.00 | 2024 | Tezspire |
| Galderma Laboratories, L.P. | $16.65 | 2025 | Nemluvio |
| Genentech USA, INC. | $16.19 | 2024 | Xolair |
| Kaleo, INC. | $15.93 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.